SPX4,057.09-19.48 -0.48%
DIA343.73-0.69 -0.20%
IXIC11,405.30-77.15 -0.67%

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

MT Newswires · 11/16/2022 03:07

Please log in to view news